Adaptive Biotechnologies posts 2025 results update

Adaptive Biotechnologies Corporation reported that it issued a press release with its financial results for the quarter and year ended December 31, 2025.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corporation reported that it issued a press release with its financial results for the quarter and year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report. The company also furnished an investor presentation, dated the same day, as Exhibit 99.2, which management may use in meetings with investors and analysts. Both the earnings release and the presentation are being furnished rather than filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 7.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Adaptive Biotechnologies (ADPT) disclose in this Form 8-K?

Adaptive Biotechnologies disclosed that it issued a press release with financial results for the quarter and year ended December 31, 2025, and furnished an investor presentation for use in meetings with investors and analysts.

Which exhibits are attached to Adaptive Biotechnologies (ADPT) January 12, 2026 Form 8-K?

The report includes Exhibit 99.1, a press release dated January 12, 2026, Exhibit 99.2, an investor presentation dated January 12, 2026, and Exhibit 104, the cover page interactive data file.

Are Adaptive Biotechnologies’ Q4 and full-year 2025 results considered filed with the SEC?

No. The company states that the information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is being furnished, not filed, and will only be incorporated into other filings if expressly referenced.

What time period do the Adaptive Biotechnologies (ADPT) financial results in the press release cover?

The press release covers the company’s financial results for the quarter and year ended December 31, 2025.

How does Adaptive Biotechnologies plan to use the investor presentation referenced in the 8-K?

Management intends to use the investor presentation in one or more meetings with investors, analysts, and others, and may modify it over time, while specifically disclaiming any obligation to update it.

Who signed the Adaptive Biotechnologies (ADPT) Form 8-K dated January 12, 2026?

The Form 8-K was signed on behalf of Adaptive Biotechnologies Corporation by Kyle Piskel, the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 08:15 AM Learn about SEC filing dates

Adaptive Biotechnologies Corp false 0001478320 0001478320 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Washington		001-38957		27-0907024
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1165 Eastlake Avenue East Seattle, Washington		98109
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ADPT		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure

The Company is furnishing presentation materials (the “Investor Presentation”) that management intends to use, possibly with modifications, in one or more meetings from time to time with investors, analysts and others. While the Company may elect to update the Investor Presentation in the future, the Company specifically disclaims any obligation to do so. The Investor Presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference.

The information in this Item 7.01 and the Investor Presentation attached as Exhibit 99.2 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated January 12, 2026
99.2		Investor Presentation dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				Adaptive Biotechnologies Corporation
Date: January 12, 2026				By:		/s/ Kyle Piskel
						Kyle Piskel
						Chief Financial Officer